MAPKs activation and mitochondrial depletion are associated with chemotherapy-related cachexia by Barreto, Rafael et al.
MAPKs activation and mitochondrial depletion are associated with chemotherapy-related cachexia 
 
Rafael Barreto1, David L. Waning2,3,5, Hongyu Gao4, Yunlong Liu4, Teresa A. Zimmers1,2,5, Andrea Bonetto1,2,5 
 
 
1Department of Surgery, 2Simon Cancer Center, 3Department of Medicine, 4Department of Medical and Molecular 
Genetics, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, 
Indianapolis, IN 46202, USA; 5IUPUI Center for Cachexia Research, Innovation and Therapy, Indianapolis, IN 
46202, USA 
 
 
Background. Cachexia, defined by increased fatigue and loss of muscle function, results from muscle and fat 
depletion and affects the majority of cancer patients with no effective treatments. Previous studies suggest that 
chemotherapy itself may contribute to cachexia, although the mechanisms responsible for these derangements 
are not clear. The purpose of this study was to investigate the mechanism(s) associated with chemotherapy-
related effects on body composition and muscle function.  
Methods. Chemotherapy regimens routinely used for the therapy of solid tumors were tested in normal CD2F1 
mice, followed by assessment of body composition and muscle strength. Mitochondrial activity in muscle sections 
was evaluated, and TEM imaging in EDL muscle was performed. To determine whether chemotherapy modulates 
signaling pathways associated with the regulation of muscle mass, Western blotting, qRT-PCR and RNA-
Sequencing were utilized.  
Results. Administration of Folfox (5-FU, leucovorin, oxaliplatin), Folfiri (5-FU, leucovorin, irinotecan) or 
Gemcitabine/Paclitaxel for up to 5 weeks to normal mice caused marked decreases in adipose tissue and skeletal 
muscle content, coherent with reduced muscle strength. Notably, ERK1/2/MAPK and p38/MAPK signaling 
pathways, as well as myostatin expression were significantly up-regulated. TEM analysis unveiled a marked 
depletion in muscle mitochondrial content and alterations of the sarcomeric structure consistent with loss of 
muscle structural proteins in the mice receiving chemotherapy. Moreover, the RNA-Sequencing analysis identified 
several markers associated with mitochondrial homeostasis, lipid metabolism and acute phase response that 
were significantly affected by Folfiri administration.  
Conclusions. Our findings suggest that chemotherapy promotes the activation of MAPK- and myostatin-
dependent muscle atrophy and causes mitochondrial depletion and alterations of the sarcomeric units, likely 
playing a causative role in the occurrence of muscle loss and weakness. Future investigations will clarify whether 
pharmacologically increasing muscle mass or inhibiting MAPK activation reduces chemotherapy-related cachexia, 
thereby providing potential pharmacological targets to improve efficacy and tolerance of anticancer drugs. 
 
 
 
